Literature DB >> 9886310

Dyskeratosis Congenita (DC) Registry: identification of new features of DC.

S Knight1, T Vulliamy, A Copplestone, E Gluckman, P Mason, I Dokal.   

Abstract

Dyskeratosis congenita (DC) is an inherited disorder characterized by skin pigmentation, nail dystrophy and mucosal leucoplakia. In 1995 a Dyskeratosis Congenita Registry was established at the Hammersmith Hospital. In the 46 families recruited, 76/83 patients were male, suggesting that the major form of DC is X-linked. As well as a variety of noncutaneous abnormalities, the majority (93%) of patients had bone marrow (BM) failure and this was the principal cause (71%) of early mortality. In addition to BM hypoplasia, some patients also developed myelodysplasia and acute myelod leukaemia. Pulmonary abnormalities were present in 19% of patients. In affected females the phenotype was less severe. Some female carriers of X-linked DC had clinical features. Carriers of X-linked DC showed skewed X-chromosome inactivation patterns (XCIPs), suggesting that cells expressing the normal DC allele have a growth/survival advantage over cells that express the mutant allele. Linkage analysis in multiplex families confirmed that the DKC1 gene, responsible for the X-linked form of DC, is located within Xq28 and facilitated its positional cloning. The high incidence of BM failure in association with a wide range of somatic abnormalities together with the ubiquitous expression of DKC1 suggest that, as well as having a critical role in normal haemopoiesis, this gene has a key role in normal cell biology.

Entities:  

Mesh:

Year:  1998        PMID: 9886310     DOI: 10.1046/j.1365-2141.1998.01103.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  44 in total

1.  A boy with breathlessness, digital clubbing and central cyanosis.

Authors:  Sanne J Gordijn; Paul L P Brand
Journal:  Eur J Pediatr       Date:  2003-12-03       Impact factor: 3.183

2.  Reduced intensity conditioning regimen with fludarabine, cyclophosphamide, low dose TBI and alemtuzumab leading to successful unrelated umbilical cord stem cell engraftment and survival in two children with dyskeratosis congenita.

Authors:  M Brown; D Myers; N Shreve; R Rahmetullah; M Radhi
Journal:  Bone Marrow Transplant       Date:  2016-01-25       Impact factor: 5.483

3.  Inactivation of the tumor suppressor genes causing the hereditary syndromes predisposing to head and neck cancer via promoter hypermethylation in sporadic head and neck cancers.

Authors:  Ian M Smith; Suhail K Mithani; Wojciech K Mydlarz; Steven S Chang; Joseph A Califano
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  2010-03-24       Impact factor: 1.538

4.  TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements.

Authors:  Hong-Yan Du; Elena Pumbo; Jennifer Ivanovich; Ping An; Richard T Maziarz; Ulrike M Reiss; Deborah Chirnomas; Akiko Shimamura; Adrianna Vlachos; Jeffrey M Lipton; Rakesh K Goyal; Frederick Goldman; David B Wilson; Philip J Mason; Monica Bessler
Journal:  Blood       Date:  2008-10-17       Impact factor: 22.113

Review 5.  Current insights into the diagnosis and treatment of inherited bone marrow failure syndromes in China.

Authors:  Xiaofan Zhu
Journal:  Stem Cell Investig       Date:  2015-08-06

6.  Liver Transplantation After Bone Marrow Transplantation for End Stage Liver Disease with Severe Hepatopulmonary Syndrome in Dyskeratosis Congenita: A Literature First.

Authors:  Shyam Sunder Mahansaria; Senthil Kumar; Kishore G S Bharathy; Sachin Kumar; Viniyendra Pamecha
Journal:  J Clin Exp Hepatol       Date:  2015-11-12

Review 7.  Dyskeratosis congenita: a disorder of defective telomere maintenance?

Authors:  Amanda J Walne; Anna Marrone; Inderjeet Dokal
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

8.  Intensive immunosuppression therapy for aplastic anemia associated with dyskeratosis congenita: report of a case.

Authors:  Patrizia Comoli; Sabrina Basso; Guan-Cheng Huanga
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

Review 9.  Telomere diseases.

Authors:  Rodrigo T Calado; Neal S Young
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

10.  Clonal hematopoiesis in patients with dyskeratosis congenita.

Authors:  Nieves Perdigones; Juan C Perin; Irene Schiano; Peter Nicholas; Jaclyn A Biegel; Philip J Mason; Daria V Babushok; Monica Bessler
Journal:  Am J Hematol       Date:  2016-10-21       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.